As of 2024-12-12, the Relative Valuation of Kymera Therapeutics Inc (KYMR) is (71.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 45.02 USD, the upside of Kymera Therapeutics Inc based on Relative Valuation is -258.5%.
The range of the Relative Valuation is (72.76) - (76.38) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.1x - 40.9x | 34.7x |
| Forward P/E multiples | 19.8x - 29.5x | 20.5x |
| Fair Price | (72.76) - (76.38) | (71.36) |
| Upside | -261.6% - -269.7% | -258.5% |
| Date | P/E |
| 2024-11-25 | -18.18 |
| 2024-11-22 | -17.40 |
| 2024-11-21 | -16.83 |
| 2024-11-20 | -17.04 |
| 2024-11-19 | -16.57 |
| 2024-11-18 | -16.40 |
| 2024-11-15 | -16.23 |
| 2024-11-14 | -17.77 |
| 2024-11-13 | -18.81 |
| 2024-11-12 | -19.34 |
| 2024-11-11 | -20.05 |
| 2024-11-08 | -19.70 |
| 2024-11-07 | -19.28 |
| 2024-11-06 | -19.14 |
| 2024-11-05 | -18.44 |
| 2024-11-04 | -18.20 |
| 2024-11-01 | -17.97 |
| 2024-10-31 | -17.86 |
| 2024-10-30 | -18.44 |
| 2024-10-29 | -18.75 |
| 2024-10-28 | -18.98 |
| 2024-10-25 | -18.56 |
| 2024-10-24 | -18.85 |
| 2024-10-23 | -18.86 |
| 2024-10-22 | -18.71 |
| 2024-10-21 | -18.01 |
| 2024-10-18 | -17.95 |
| 2024-10-17 | -17.89 |
| 2024-10-16 | -18.96 |
| 2024-10-15 | -17.33 |
| 2024-10-14 | -17.81 |
| 2024-10-11 | -17.41 |
| 2024-10-10 | -16.72 |
| 2024-10-09 | -16.76 |
| 2024-10-08 | -16.65 |
| 2024-10-07 | -16.32 |
| 2024-10-04 | -16.65 |
| 2024-10-03 | -16.79 |
| 2024-10-02 | -17.40 |
| 2024-10-01 | -18.01 |
| 2024-09-30 | -18.30 |
| 2024-09-27 | -18.83 |
| 2024-09-26 | -19.13 |
| 2024-09-25 | -20.08 |
| 2024-09-24 | -20.27 |
| 2024-09-23 | -19.33 |
| 2024-09-20 | -19.26 |
| 2024-09-19 | -18.96 |
| 2024-09-18 | -17.96 |
| 2024-09-17 | -18.29 |